Skip to content
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
  • Country/Region
  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
  • Part of brands: |
InternationalInternational
  • Country/Region
  • Part of brands: |
  • We guide you
    • Before Pregnant
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ALICE
      • EMMA
      • ERA
      • EndomeTRIO
      • EMBRACE
      • CGT
      • Infertility Panels
      • NACE
      • Zenit
      • PGT-A
      • Smart PGT-A Plus
      • PGT-M
      • POC
      • SAT
      • Newborn Screening
    • Patients
      • ALICE
      • EMMA
      • ERA
      • EndomeTRIO
      • EMBRACE
      • CGT
      • NACE
      • Zenit
      • PGT-A
      • Smart PGT-A Plus
      • PGT-M
      • SAT
      • POC
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
  • We guide you
    • Fertility
      • What to do if…
    • Prevent Inherited Diseases
      • Carrier Genetic Test
    • Worry-free Pregnancy
      • NACE
      • Prenatal Diagnostics
      • Newborn Health
Genomics Precision Diagnostic > Rheumatology Precision Panel > Systemic Lupus Erythematosus Precision Panel

Systemic Lupus Erythematosus Precision Panel

Systemic Lupus Erythematosus is a chronic multisystemic autoimmune disease of unknown cause. The most prominent feature of this disease is the onset of immunologic abnormalities, especially the production of antinuclear antibodies.
Rheumatology
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • Systemic Lupus Erythematosus is a chronic multisystemic autoimmune disease of unknown cause. The most prominent feature of this disease is the onset of immunologic abnormalities, especially the production of antinuclear antibodies. These antibodies chase for nuclear and cytoplasmatic antigens, which causes multisystem inflammation and protean clinical manifestations, among other symptoms. Although the dermatologic manifestation is the most representative feature, this disorder can affect any tissue or system in a wide range of intensity, causing from mild joint and skin involvement to life-threatening renal, hematologic and nervous system involvement. The mode of inheritance varies from autosomal dominant to recessive.  

  • The Igenomix Systemic Lupus Erythematosus Precision Panel can be used to make an accurate and directed diagnosis as well as a differential diagnosis of arthritis ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.

Indication

  • The Igenomix Systemic Lupus Erythematosus Precision Panel is indicated for those patients with a clinical diagnosis or suspicion presenting with or without the following manifestations: 
    • Arthritis and arthralgias 
    • Facial eruption 
    • Cardiac involvement: Pericarditis and pericardial effusion. 
    • Vascular manifestations: Erythroderma, vasculitis, venous thrombotic event, Raynaud phenomenon. 
    • Gastrointestinal involvement: esophagitis, pancreatitis, peritonitis. 
    • Pulmonary involvement: pleuritis, pneumonitis, interstitial lung disease, alveolar haemorrhage. 
    • Neurologic involvement: Stroke, seizures, cognitive dysfunction, peripheral neuropathies. 
    • Hematologic abnormalities: Anemia of chronic disease, leukopenia, thrombocytopenia. 
    • Ophthalmologic involvement: Sjögren’s Syndrome, retinal vasculopathy, scleritis. 
    • Osteoporosis and osteonecrosis. 

Clinical Utility

The clinical utility of this panel is: 

  • The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.  
  • Early initiation of multidisciplinary treatment including mainly pharmacologic treatment with hydroxychloroquine or chloroquine to relief constitutional symptoms, musculoskeletal manifestations and mucocutaneous manifestations. High doses of systemic glucocorticoids (such as methylprednisolone) can be considered as well if secondary manifestations are life-threatening.  
  • Periodic follow up with cardiologist, rheumatologist, ophthalmologist and dermatologist.  
  • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance. 
  • Improvement of delineation of genotype-phenotype correlation. 

Genes & Diseases

Methodology

References

See scientific referrals

Wallace D. J. (2008). Improving the prognosis of SLE without prescribing lupus drugs and the primary care paradox. Lupus, 17(2), 91–92. 

Bertsias, G., Ioannidis, J. P., Boletis, J., Bombardieri, S., Cervera, R., Dostal, C., Font, J., Gilboe, I. M., Houssiau, F., Huizinga, T., Isenberg, D., Kallenberg, C. G., Khamashta, M., Piette, J. C., Schneider, M., Smolen, J., Sturfelt, G., Tincani, A., van Vollenhoven, R., Gordon, C., … Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (2008). EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Annals of the rheumatic diseases, 67(2), 195–205. 

Jolly M. (2010). Pitfalls and opportunities in measuring patient outcomes in lupus. Current rheumatology reports, 12(4), 229–236. 

descargar

Detail description

Download

Request Information


WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Complaints
Work with us

FOLLOW IGENOMIX

  + 96 390 53 10
  Write us
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
Country/Region

[2021] © Igenomix Privacy policy Quality policy Legal note Cookies policyNews and Press

Request Information


  • We guide you
    • Before Pregnant
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ALICE
      • EMMA
      • ERA
      • EndomeTRIO
      • EMBRACE
      • CGT
      • Infertility Panels
      • NACE
      • Zenit
      • PGT-A
      • Smart PGT-A Plus
      • PGT-M
      • POC
      • SAT
      • Newborn Screening
    • Patients
      • ALICE
      • EMMA
      • ERA
      • EndomeTRIO
      • EMBRACE
      • CGT
      • NACE
      • Zenit
      • PGT-A
      • Smart PGT-A Plus
      • PGT-M
      • SAT
      • POC
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
  • We guide you
    • Fertility
      • What to do if…
    • Prevent Inherited Diseases
      • Carrier Genetic Test
    • Worry-free Pregnancy
      • NACE
      • Prenatal Diagnostics
      • Newborn Health
  • Country/Region
  • +34 96 390 53 10
  • Clinic Portal
  • Request Information

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

International
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Cookie Policy

More information about our Cookie Policy